In the past decade clinical and laboratory studies have led to important new insights into the
biology of chronic myeloid leukemia (CML). Basic science has defined the molecular …

Updated findings from a randomised comparison of imatinib versus previous standard
treatment in the treatment of newly diagnosed chronic myeloid leukaemia suggest that this …

Major therapeutic progress has been accomplished in leukemia and myelodysplastic
syndrome (MDS) over the past 40 years, which may not be fully appreciated by the larger …

Treatment options for chronic myeloid leukemia (CML) have changed dramatically during
the last decades. Interferon-α treatment and stem cell transplantation (SCT) clearly improved …

Imatinib mesylate has become the treatment of choice for chronic myeloid leukemia (CML):
the standard dose for chronic-phase (CP) CML is 400 mg daily. Response rates are different …

Management strategies of patients with chronic-phase chronic myeloid leukemia (CML)
have been revolutionized by the BCR-ABL–selective kinase inhibitor imatinib, which is …

Therapy for patients with chronic myeloid leukaemia has grown in complexity, first with the
advent of the prototype ABL kinase inhibitor, imatinib, and subsequently with the availability …

Imatinib dosing in patients with chronic myeloid leukemia (CML) is flat, as pharmacokinetic
(PK) studies showed that plasma trough concentrations are correlated with dose, whereas …

Imatinib and other Abl tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib, have
significantly improved the outcome of patients with chronic myeloid leukemia. Imatinib and …

BACKGROUND: Chronic myeloid leukemia (CML) is most often caused by the translocation
of chromosomes 9 and 22 to create the fusion protein, BCR-ABL. This constitutively active …